Protocol Ledger

NCT05181540 · Phase III · TERMINATED

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Interventional Phase III clinical trial protocol NCT05181540 sponsored by Angiocrine Bioscience in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-21 Enrollment: 130 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05181540
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05181540
Protocol FieldVerified Registry Value
NCT IdentifierNCT05181540
Consolidated Lead SponsorAngiocrine Bioscience
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment130 participants (ACTUAL)
Registered Start Date2022-02-21
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI